Bio-Rad plans to drive adoption of Stilla's all-in-one Nio+ dPCR system while also incorporating its own assays to expand the menu.
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.

Demand remains low, but lab stakeholders said the industry is significantly better prepared to meet a spike in H5N1 testing needs than it was during the COVID-19 pandemic.
Genomictree Closing in on South Korea Approval for Bladder Cancer MDx, Aims to Begin US Trials Soon
Premium
Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.
Babson Diagnostics Prepares for Broader Commercialization of Blood Collection System in 2025
Premium
The firm has developed a fingertip blood collection device that can be used in multiple healthcare settings.
Researchers have begun validating the new method that can reduce lab contamination and obviate the need for lyophilization.